[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Institute of Cardiovascular Diseases, Pakistan\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":264},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,85,115,142,171,201,222,243],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100647805","phase-3-ivabradine-in-the-acute-management-of-cardiogenic-shock-100647805",false,"NCT07714746","Ivabradine in the Acute Management of Cardiogenic Shock","Ivabradine in the Acute Management of Cardiogenic Shock - IVASHOCK-a Double-blind Randomized Controlled Trial","IVASHOCK","Inclusion Criteria:\n\n* Patients aged 18-75 years diagnosed with STEMI complicated by cardiogenic shock (CS) as defined by SCAI shock classification \\> C:\n\nSigns of Hypoperfusion including:\n\n1. SBP \\\u003C90 OR MAP \\\u003C60 OR \\>30 mmHg drop from baseline AND drugs\u002Fdevice used to maintain BP above these targets\n2. Cold, clammy extremities\n3. Urine output \\\u003C30 mL\u002Fh\n4. pulmonary congestion (either crackles, congestion in chest X-ray or B-lines in lung US)\n5. Mixed venous oxygen saturation ≤ 65%\n\n   * Severe Left ventricular (LV) dysfunction or right ventricular (RV) infarction\n   * Heart rate (HR) ≥ 100 bpm (Sinus Rhythm) in whom beta-blocker therapy cannot be initiated, including: On inotropic or vasopressor support, Requiring an intra-aortic balloon pump (IABP), With Killip class III or IV, Requiring BiPAP or mechanical ventilation\n\nExclusion Criteria:\n\n* Age \\> 75 years\n* CPR \\> 12 mints\n* Atrial fibrillation\n* Complete Heart Block\n* Heart rate of \\\u003C 100 bpm\n* End stage Renal Disease\n* Extensive comorbidities; Prior CVA, Malignancy, Pregnancy or Ongoing Participation in Other Trials","ALL","18 Years","75 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Brief Summary:\n\nThe IVASHOCK trial investigates whether ivabradine can achieve at least one-class improvement in SCAI cardiogenic shock classification compared to placebo, and evaluates its safety profile in patients with cardiogenic shock (CS).\n\nPrimary Objectives:\n\n1. To determine whether ivabradine improves SCAI shock classification by at least one class from baseline within 72 hours compared to placebo\n2. To assess whether ivabradine facilitates earlier weaning from vasoactive and inotropic support compared to placebo\n\nSafety Endpoints:\n\nAdverse events monitored include: sinus node dysfunction, new-onset atrial fibrillation or atrial flutter, atrioventricular block, drug-related hypotension, and ventricular arrhythmia.\n\nParticipant Schedule:\n\nParticipants will receive ivabradine or placebo orally every 12 hours for 3 days.\n\nHemodynamic and metabolic assessments will include:\n\nArterial pH, central venous oxygen saturation (ScvO2), and serum lactate - every 6 hours on Day 1, then every 8 hours on Days 2 and 3 Heart rate, mean arterial pressure (MAP), vasoactive\u002Finotropic support dose, and urine output - measured on the same timeline",[28],"Cardiogenic Shock Post Myocardial Infarction",[30,31,32,33,34,35],"ivabradine","cardiogenic shock","SCAI Shock Stage Classification","Heart Rate Reduction","Randomized clinical trial","Shock Severity Improvement","RECRUITING","2026-07-14",{"date":39,"type":40},"2026-07-20","ACTUAL",{"date":42,"type":40},"2026-04-20",{"date":44,"type":22},"2027-05-31",{"name":46,"class":47},"National Institute of Cardiovascular Diseases, Pakistan","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":4},"100645903","phase-4-comparing-the-efficacy-and-safety-of-vericiguat-with-standard-medical-treatment-in-heart-failure-patients-100645903","NCT07697833","Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients","Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Patients With Heart Failure and Reduced Ejection Fraction: Randomized, Placebo-controlled, Parallel-group, Double-blind Trial","VERICIGUAT","Inclusion Criteria:\n\n1. Age \\>18 years of any gender\n2. Chronic heart failure (New York Heart Association \\[NYHA\\] functional class II, III, or IV), a reduced left ventricular ejection fraction of less than 45% within 12 months before randomization\n3. Elevated natriuretic peptide level: (For patients in sinus rhythm, the criteria include a plasma B-type natriuretic peptide (BNP) level of at least 300 pg per milliliter or an NT-proBNP level of at least 1000 pg per milliliter. For patients in atrial fibrillation, the criteria included a BNP level of at least 500 pg per milliliter or an NT-proBNP level of at least 1600 pg per milliliter).\n4. Evidence of worsening heart failure.\n5. The percentage of enrolled patients with an estimated glomerular filtration rate of 15 to 30 ml per minute per 1.73 m2 of body-surface area was capped at 15%.\n6. Patients on guideline-based medical therapy 3 months\n7. Written and informed consent.\n\nExclusion Criteria:\n\n1. Systolic blood pressure of less than 100 mm Hg.\n2. Concurrent or anticipated use of long-acting nitrates.\n3. Use of intravenous inotropes or implantable left ventricular assist devices.\n4. Not on standard of care medical treatment for heart failure.\n5. Unwillingness to give consent","80 Years",{"count":59,"type":22},500,[61],"PHASE4","To compare the effectiveness and safety of Vericiguat with Standard Medical Treatment in Patients with Heart Failure and Reduced Ejection Fraction",[64],"Heart Failure With Reduced Ejection Fraction (HFrEF)",[66,67,68,69,70,71,72,73,74,75],"Vericiguat","Heart Failure","Reduced Ejection Fraction (HFrEF)","Chronic Heart Failure","Cardiovascular Diseases","Randomized Controlled Trial","Double Blind","Placebo-Controlled","Soluble Guanylate Cyclase Stimulator","NT-proBNP","NOT_YET_RECRUITING","2026-07-10",{"date":79,"type":40},"2026-07-13",{"date":81,"type":22},"2026-07-15",{"date":83,"type":22},"2027-07-31",{"name":46,"class":47},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":102,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},"100634216","phase-4-adenosine-pre-medication-in-primary-percutaneous-coronary-intervention-100634216","NCT07536802","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention","Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial","AMPACT","Inclusion Criteria:\n\n* All patients with acute STEMI undergoing primary PCI\n* Patients of either sex, ≥18 years of age.\n\nExclusion Criteria:\n\n* STEMI patients with cardiogenic shock at presentation\n* Patients with heart block\n* Allergy to adenosine\n* Patients refuse to give consent for participation",{"count":94,"type":22},1148,[61],"Primary objective of the study is to evaluate the impact of adenosine pre-medication on incidence of slow flow\u002Fno-reflow after primary percutaneous coronary intervention.",[98,99,100,101],"ST-Segment Elevation Myocardial Infarction (STEMI)","No-Reflow Phenomenon","Coronary Slow Flow","Acute Myocardial Infarction",[103,104,98,99,100,105],"Adenonsine","Primary Percutaneous Coronary Intervention (Primary PCI)","Myocardial Reperfusion","2026-04-17",{"date":108,"type":40},"2026-04-22",{"date":110,"type":40},"2025-06-01",{"date":112,"type":22},"2026-12-31",{"name":46,"class":47},2,{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":123,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":125,"targetDuration":127,"studyType":128,"phases":4,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":48},"100554765","a-hospital-based-registry-of-preventive-cardiology-clinics-100554765","NCT06503341","A Hospital-Based Registry of Preventive Cardiology Clinics","Assessment and Control of Modifiable Risk Factors for Primary and Secondary Prevention","PREVENT-CARD","Inclusion Criteria:\n\n* All individuals attending the preventive cardiology clinics.\n\nExclusion Criteria:\n\n* • Individuals who refused to give consent.",true,"90 Years",{"count":126,"type":22},10000,"10 Years","OBSERVATIONAL","More research is needed to articulate the most effective ways to use these tools as screening tests in cardiovascular risk assessments and how they ultimately affect CVD mortality and morbidity outcomes. Clinicians are encouraged to continue sharing decision-making with patients to combine their unique cardiovascular risk factors and develop a comprehensive, effective treatment plan.",[131,132,133],"Cardiovascular Morbidity","Cardiovascular Risk Assesment","Primary Prevention CVD","2026-04-09",{"date":136,"type":40},"2026-04-13",{"date":138,"type":40},"2021-06-17",{"date":140,"type":22},"2041-06-01",{"name":46,"class":47},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":23,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":48},"100610566","phase-3-dcb-vs-des-in-young-stemi-patients-the-dcb-stemi-trial-100610566","NCT07229248","DCB vs. DES in Young STEMI Patients: The DCB-STEMI Trial","Drug Coated Balloon vs. Drug Eluting Stent in Young Patients With STEMI: The DCB-STEMI Randomized Trial","DCB-STEMI","Inclusion Criteria:\n\n* Either gender\n* Patient of age between 18 to 50 years\n* Patients with STEMI ( as first presentation of CAD) undergoing Primary PCI\n* Total ischemic Time less than 8 hrs.\n* Low syntax score\n* Stable (Killip I-II)\n\nExclusion Criteria:\n\n* Patients with ESRD\n* Severe 3 VD; Intermediate of High syntax score\n* Lesion type\\>B","49 Years",{"count":152,"type":22},496,[25],"Background: ST Elevation Myocardial Infarction (STEMI) in young adults (\\\u003C50 yrs) carries high Percutaneous coronary intervention (PCI) risks. While drug-eluting stents (DES) reduce restenosis versus angioplasty, they increase risks of in-stent restenosis, thrombosis, prolonged dual antiplatelet therapy (DAPT), and endothelial dysfunction. Drug-coated balloons (DCB) provide a \"leave nothing behind\" strategy, potentially mitigating these issues. Evidence, including a JACC CVI report, suggests DCB outcomes comparable to DES in STEMI. South Asia faces a heavy burden. The national Institute of Cardiovascular diseases (NICVD), Karachi performed 17,761 primary PCIs in 2022, with 45% in patients \\\u003C50 yrs.\n\nStudy Design: This single-center Randomized Controlled Trial (RCT) compares paclitaxel-coated DCB (3.0 µg\u002Fmm², 30s inflation) vs. Drug eluting stents (DES) in young STEMI patients (\\\u003C50 yrs) undergoing primary PCI. The primary endpoint is 1-year vessel oriented cardiac events (VOCE)= Cardiovascular \u002Fall-cause death, target vessel MI, or Target lesion revascularization (TLR). Secondary endpoints include vessel-oriented CV events, bleeding, TIMI III flow, residual stenosis, abrupt closure, and bailout stenting. An intravascular ultrasound (IVUS) substudy (100 DCB pts) will evaluate remodeling and late lumen loss (LLL) at 6 months.\n\nMethods: 496 patients (248\u002Farm) will be randomized 1:1, powered for non-inferiority (margin 4.5%) assuming VOCE 8.5% (DES) vs. 6.25% (DCB), 80% power, and 5% dropout. Inclusion: age 18-50, STEMI. Exclusion: End stage renal disease (ESRD), severe multivessel disease, complex lesions, or high thrombus burden. All will receive ticagrelor 90 mg BID for 1 month. A pilot of 50 pts will first assess safety (abrupt closure, lesion prep).\n\nAnalysis: Intention-to-treat (ITT) will be primary; modified ITT for secondary endpoints. Statistics include chi-square\u002FFisher for categorical, t-test\u002FWilcoxon for continuous, and Kaplan-Meier\u002FCox for survival. Oversight by data safety monitoring board (DSMB) and Events adjudication Committee (EAC).\n\nSignificance: This trial leverages NICVD's high PCI volume to test DCB as an alternative to DES in young STEMI patients. By avoiding permanent implants, DCB may reduce long-term complications and DAPT needs. The IVUS substudy and pilot phase strengthen rigor. If non-inferiority is proven, DCB could reshape STEMI management in South Asia and similar high-burden regions.",[156],"STEMI (ST Elevation MI)",[158,159,160,161,162],"Drug coated balloon","STEMI","RCT","DES","MACE","2025-11-13",{"date":165,"type":40},"2025-11-14",{"date":167,"type":22},"2025-11-05",{"date":169,"type":22},"2027-12-26",{"name":46,"class":47},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":48},"100573152","phase-3-apixaban-prophylaxis-for-prevention-of-left-ventricular-thrombus-following-anterior-myocardial-infarction-100573152","NCT06742567","Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction","Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction: An Open Label, Randomized Clinical Trial (POTAMI)","POTAMI","Inclusion Criteria:\n\n* Patients aged 18-65 years\n* Presenting with acute anterior STEMI\n* Severe LV dysfunction (EF\\\u003C35%) with antero-apical akinesis, dyskinesis, or aneurysm\n* WIHTOUT evidence of LV thrombus.\n\nExclusion Criteria:\n\n* Patients with previous anterior myocardial infarction or LAD revascularization procedures\n* Patients with cardiogenic shock\n* Patients with LV thrombus\n* Patients with advanced CKD (Cr \\> 2 and those on hemodialysis)\n* Recent ICH or major bleed requiring transfusion, low platelet counts \\\u003C100,000\n* History of recent CVA ( within past three months)\n* Patients with atrial fibrillation or other indications for chronic anticoagulation\n* Pregnant patients and those with hematological disorders",{"count":180,"type":22},472,[25],"The objective of this randomized controlled trial is to compare the safety and efficacy of low dose Apixaban (2.5 mg bid) in addition to guideline directed medical therapy vs guideline directed medical therapy alone in the prevention of left ventricular thrombus formation (after 30-days) following primary PCI in patients with acute anterior myocardial infarction with severe LV dysfunction.",[184,185,186],"Acute Myocardial Infarction of Anterior Wall","Left Ventricular Thrombus","Prophylaxis",[188,189,190,191,192],"Acute myocardial infarction","severe left ventricular dysfunction","prevention of LV thrombus","DOAC","apixaban","2024-12-17",{"date":195,"type":40},"2024-12-19",{"date":197,"type":40},"2024-12-02",{"date":199,"type":22},"2025-11-30",{"name":46,"class":47},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":208,"targetDuration":210,"studyType":128,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":48},"100547972","prognostic-model-heart-failure-100547972","NCT06414928","Prognostic Model Heart Failure","In-hospital & 30-day Prognostication of Acute Heart Failure Patients by Comparing 4 Validated Scores in Patients Presenting to the Emergency Department of Cardiac Tertiary Care Hospital, Karachi- Pakistan","Inclusion Criteria:\n\n* Patients of age \\> 18 years or more\n* Either gender\n* Patients visited the emergency department at NICVD, Karachi\n* Newly\u002FAlready diagnosed with Heart Failure\n* Giving informed consent\n* Who can be followed in 30 days via Telephone or in OPD\n\nExclusion Criteria:\n\n* Patients of age \\\u003C18 years\n* Patients who do not give consent\n* Patients who are mentally handicapped due to any neurological or psychiatric illness (excluding depression\u002Fanxiety)",{"count":209,"type":22},1000,"30 Days","This study aims to determine the prognosis of heart failure in our population by using multiple validated risk scores and to evaluate the strengths of these scores in assessing prognosis with better discrimination.",[213],"Heart Failure Acute","2024-05-10",{"date":216,"type":40},"2024-05-16",{"date":218,"type":40},"2024-02-14",{"date":220,"type":22},"2026-06-14",{"name":46,"class":47},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":229,"minAge":4,"maxAge":4,"enrollmentInfo":230,"targetDuration":231,"studyType":128,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":48},"100516440","prospective-pakistan-registry-of-echocardiographic-screening-in-asymptomatic-pregnant-women-100516440","NCT06004544","Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women","PRESAP","Inclusion Criteria:\n\n* Obstetric patients attending routine antenatal visits\n\nExclusion Criteria:\n\n* Patients refused to give consent for echocardiography or participation in the study","FEMALE",{"count":126,"type":22},"1 Year","Consecutive obstetric patients attending routine antenatal visits were enrolled in this ongoing registry. A standardized 2D transthoracic echocardiogram (TTE) protocol was employed. Ejection fraction (EF) was quantified using biplane Simpson's method.",[234],"Cardiovascular Diseases in Pregnancy","2023-08-27",{"date":237,"type":40},"2023-08-30",{"date":239,"type":40},"2023-02-06",{"date":241,"type":22},"2028-12-31",{"name":46,"class":47},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":123,"sex":17,"minAge":127,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":128,"phases":4,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":263,"locationsCount":48},"100515416","screening-and-secondary-prevention-rheumatic-heart-disease-study-100515416","NCT05991219","Screening and Secondary Prevention Rheumatic Heart Disease Study","Screening and Secondary Prevention Rheumatic Heart Disease","S2-RHD","Inclusion Criteria:\n\n* Rural communities in Sindh\n\nExclusion Criteria:\n\n* Refused to participate in the study","30 Years",{"count":253,"type":22},5000,"After basic clinical screening including history and physical, Point of care ultrasound will be performed to look at Mitral, Aortic and Tricuspid Valves for regurgitation or stenosis. For patients with confirmed Rheumatic heart disease (RHD), treatment and referral depending on stage of disease. Antibiotic prescription could be shifted to community health workers delivering preventive medications via practical clinical algorithms, diagnostic tools, availability of appropriate antibiotics, and supportive supervision. Patients will have repeat imaging at 2 years and 5 years to look at the outcome of delayed progression of valve disease.",[256],"Rheumatic Heart Disease","2023-08-12",{"date":259,"type":40},"2023-08-15",{"date":261,"type":40},"2022-09-26",{"date":241,"type":22},{"name":46,"class":47},""]